SCHEMBL5673448

SCHEMBL5673448

Cc1cc2cccc(Cl)c2n1CCC(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CMA1 P23946 2/20 0.51
CCR2 P41597 1/20 0.46
ALDH1A1 P00352 3/20 0.43
CCR9 P51686 1/20 0.41
KMO O15229 2/20 0.41
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 2/20 0.41
FABP3 P05413 1/20 0.40
FABP4 P15090 1/20 0.40
FABP5 Q01469 1/20 0.40
MAPT P10636 3/20 0.39
P2RX3 P56373 2/20 0.39
APEX1 P27695 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
CYP1A2 P05177 1/20 0.39
HSP90AA1 P07900 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20048466 0.85 CCR2 (0.51) CMA1CCR2CCR9KDM4EKMT2A
SCHEMBL5672246 0.79 PRMT5 (0.38) CCR2ALDH1A1CCR9KDM4EMAPT
SCHEMBL5672286 0.78 CCR2 (0.37) CCR2ALDH1A1CCR9KDM4EMAPT
SCHEMBL20853335 0.77 CASR (0.42) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL10674441 0.76 ALDH1A1 (0.66) CMA1ALDH1A1KDM4EFABP3FABP4
SCHEMBL5673158 0.75 LMNA (0.44) CCR2ALDH1A1CCR9MAPK1KDM4E
SCHEMBL20037332 0.75 TSHR (0.56) ALDH1A1KDM4EMAPTKMT2AMEN1
SCHEMBL476703 0.74 CCR2 (0.35) CMA1CCR2ALDH1A1CCR9KDM4E
SCHEMBL15971121 0.74 NOTUM (0.42) CCR2ALDH1A1CCR9KDM4EMAPT
SCHEMBL20853011 0.73 CCR2 (0.38) CCR2ALDH1A1CCR9KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6995184-B2 Such as (7-chloro-2-methyl-1-(3-(methylsulphanyl)propyl)-1H-indol-3-yl)(2,3-dichloro-phenyl)methanone; cannabinoid receptors (cb2); G proteins coupled receptors SANOFI-AVENTIS (FR) 2006-02-07 US disclosed
CN-1234688-C 3-aroyl indoles and their use as CB2Use of receptor agonists SANOFI ANVANT (FR) 2006-01-04 CN disclosed
CN-1483023-A 3-arylindole derivatives and their use as cb2 receptor agonists ʥŵ��-�ϳ�ʵ���ҹ�˾ 2004-03-17 CN disclosed
US-20040034090-A1 3-Arylindole derivatives and their use as cb2 receptor agonists SANOFI-AVENTIS (FR) 2004-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034090-A1 3-Arylindole derivatives and their use as cb2 receptor agonists CNR2, CNR1, GPR52 CMA1 1674/4885CCR2 148/4885ALDH1A1 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.